Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination

Bornali Bhattacharjee(Yale University), Peiwen Lu(Yale University), Valter Silva Monteiro(Yale University), Alexandra Tabachnikova(Yale University), Kexin Wang(Yale University), William Brenham Hooper(Yale University), Victoria Cortes Bastos(Yale University), Kerrie Greene(Yale University), Mitsuaki Sawano(Yale New Haven Hospital), Christian Guirgis(Yale University), Tiffany J. Tzeng(Yale University), Frederick Warner(Yale New Haven Hospital), Pavlina Baevova(Yale University), Kathy Kamath(Serimmune (United States)), Jack Reifert(Serimmune (United States)), Danice Hertz(Film Independent), Brianne Dressen(Oldham Council), Laura Tabacof(Icahn School of Medicine at Mount Sinai), Jamie Wood(Icahn School of Medicine at Mount Sinai), Lily Cooke(Icahn School of Medicine at Mount Sinai), Mackenzie Doerstling(Icahn School of Medicine at Mount Sinai), Shadan Nolasco(Icahn School of Medicine at Mount Sinai), Amer Ahmed(Icahn School of Medicine at Mount Sinai), Amy D. Proal(Boston Foundation), David Putrino(Icahn School of Medicine at Mount Sinai), Leying Guan(Yale University), Harlan M. Krumholz(Yale New Haven Hospital), Akiko Iwasaki(Yale University)
medRxiv
February 18, 2025
Cited by 26Open Access
Full Text

Abstract

SUMMARY COVID-19 vaccines have prevented millions of COVID-19 deaths. Yet, a small fraction of the population reports a chronic debilitating condition after COVID-19 vaccination, often referred to as post- vaccination syndrome (PVS). To explore potential pathobiological features associated with PVS, we conducted a decentralized, cross-sectional study involving 42 PVS participants and 22 healthy controls enrolled in the Yale LISTEN study. Compared with controls, PVS participants exhibited differences in immune profiles, including reduced circulating memory and effector CD4 T cells (type 1 and type 2) and an increase in TNFα+ CD8 T cells. PVS participants also had lower anti-spike antibody titers, primarily due to fewer vaccine doses. Serological evidence of recent Epstein-Barr virus (EBV) reactivation was observed more frequently in PVS participants. Further, individuals with PVS exhibited elevated levels of circulating spike protein compared to healthy controls. These findings reveal potential immune differences in individuals with PVS that merit further investigation to better understand this condition and inform future research into diagnostic and therapeutic approaches.


Related Papers

No related papers found

Powered by citation graph analysis